Quality Consensus - Summary of decisions made at GAiT Quality Standards workshop
Dear all,
  • Thanks to all who attended the GAiT Quality Standards Workshop last week.
  • Please find below a summary of the key decisions made concerning critical quality attributes for iPSC lines to be considered for the GAiT haplobank network. We circulate this to all GAiT associates to make sure that our understanding of the decisions made has been faithfully captured and to allow thought and additional discussion.
    • Please note there is now a LinkedIn group for GAiT (here) in addition to the Twitter account  (@iPSCtherapies). Conversation concerning the workshop should have the hashtag #gait2017.
    • When the new GAiT website & database is up and running in the coming months, discussion boards will be included to facilitate discussion and mutual understanding.
  • We are now preparing a manuscript around the agreed consensus which will give further detail. A draft will be circulated to attendees after Board approval shortly.
  • Again, we are very grateful to Glyn Stacey, our visiting Quality Standards chair, who did an excellent job chairing.
Kind regards,
Stephen Sullivan
GAiT - the Global Alliance for iPSC Therapies
Resolution of decisions made at the GAiT iPSC Quality Standards workshop (5th October 2017 / Sheffield, UK.)
Critical Quality Attribute Recommended test method Comments
STR STR profiles
Use a commercially available kit performed by accredited personnel

Check allele coverage with GAiT

SNP or other test may be used in-house and contributed as data for information but difficulties with different algorithms mean GAiT needs data that can be compared easily across centres
Mycoplasma Qualified qPCR or culture (broth/agar or Vero inoculation/DNA stain) method Mandatory
Use of Pharmacopoeia methods
Karyotype G Banding Mandatory
SNP valuable for information and keep watching brief
Viability Dye exclusion test on thawing
Recovery of a typical iPSC culture (action NIBSC)
More than or equal to 50% viable cells
Doubling time Not required Data may be added for information
Immunophenotype Flow cytometry or immunocytochemistry of two markers which should include a self-renewal marker (Oct4) and a stem cell surface marker (e.g. TRA-1-60, SSEA4) Required but for information to show a stem cell phenotype and not a release criterion

Additional data recommended

No tolerance on levels of expression but markers positive should typically be on >70% of cells
Pluripotency assays At least one method used Required but only for information to show potential to produce each germ layer
Viral testing Based on risk assessment of cells and reagents and residual risk. Mandatory as required by risk assessment of donor and process.

Donor testing for pathogens considered relevant to cell line.
Residual vector testing Appropriate sensitive assay to be used Mandatory

Action: Stephen Sullivan to contact NIBSC regarding reference materials (also consider CIRM limit of <1 copy per 100 cells)
Differentiated cells Not required Covered by immunophenotyping
Cell debris Not required Highly unlikely impact on product
Endotoxin Required Mandatory
Use Pharmacopeia method
Labelling Not required as relevant not current discussion -
WGA and other genetic/epigenetic analysis/disease markers Not required Strongly encouraged for future reference

Thanks also to those how remained for the post-meeting dinner.

Our next meeting will be in Berlin on the 1st November 2017 and will be chaired by Andreas Kurtz. We shall
agree HLA- and clinical grade iPSC- data fields for the GAiT database. More details to follow.
Copyright © 2017 Global Alliance for iPSC Therapies, All rights reserved.

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Email Marketing Powered by Mailchimp